You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSulfadiazine
Accession NumberDB00359  (APRD00190)
Typesmall molecule
Groupsapproved
Description

One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
2-sulfanilamidopyrimidineNot AvailableNot Available
2-sulfanilylaminopyrimidineNot AvailableNot Available
4-amino-N-2-pyrimidinylbenzenesulfonamideNot AvailableNot Available
N(1)-2-PyrimidinylsulfanilamideNot AvailableNot Available
N(1)-2-PyrimidylsulfanilamideNot AvailableNot Available
N1-2-pyrimidinylsulfanilamideNot AvailableNot Available
N1-2-pyrimidylsulfanilamideNot AvailableNot Available
SulfadiazinaNot AvailableNot Available
SulfadiazineNot AvailableNot Available
SulfadiazinumNot AvailableNot Available
SulfapyrimidineNot AvailableNot Available
SulphadiazineNot AvailableNot Available
SaltsNot Available
Brand names
NameCompany
AdiazineNot Available
Brand mixturesNot Available
Categories
CAS number68-35-9
WeightAverage: 250.277
Monoisotopic: 250.052446274
Chemical FormulaC10H10N4O2S
InChI KeySEEPANYCNGTZFQ-UHFFFAOYSA-N
InChI
InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
IUPAC Name
4-amino-N-(pyrimidin-2-yl)benzene-1-sulfonamide
SMILES
NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
Mass Specshow(7.99 KB)
Taxonomy
KingdomOrganic Compounds
SuperclassBenzenoids
ClassBenzene and Substituted Derivatives
SubclassBenzenesulfonamides
Direct parentAminobenzenesulfonamides
Alternative parentsSulfonylanilines; Pyrimidines and Pyrimidine Derivatives; Primary Aromatic Amines; Sulfonyls; Sulfonamides; Polyamines
Substituentsaniline; primary aromatic amine; pyrimidine; sulfonyl; sulfonamide; sulfonic acid derivative; polyamine; amine; primary amine; organonitrogen compound
Classification descriptionThis compound belongs to the aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
Pharmacology
IndicationFor the treatment of rheumatic fever and meningococcal meningitis
PharmacodynamicsSulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
Mechanism of actionSulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationSulfadiazine is excreted largely in the urine.
Half lifeNot Available
ClearanceNot Available
ToxicityOral LD50 in mouse is 1500 mg/kg.
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9877
Blood Brain Barrier + 0.9383
Caco-2 permeable + 0.6988
P-glycoprotein substrate Non-substrate 0.9012
P-glycoprotein inhibitor I Non-inhibitor 0.913
P-glycoprotein inhibitor II Non-inhibitor 0.9156
Renal organic cation transporter Non-inhibitor 0.8437
CYP450 2C9 substrate Non-substrate 0.8031
CYP450 2D6 substrate Non-substrate 0.915
CYP450 3A4 substrate Non-substrate 0.7671
CYP450 1A2 substrate Non-inhibitor 0.9574
CYP450 2C9 substrate Non-inhibitor 0.922
CYP450 2D6 substrate Non-inhibitor 0.9548
CYP450 2C19 substrate Non-inhibitor 0.9693
CYP450 3A4 substrate Non-inhibitor 0.902
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8569
Ames test Non AMES toxic 0.9206
Carcinogenicity Non-carcinogens 0.9393
Biodegradation Not ready biodegradable 0.9973
Rat acute toxicity 1.8353 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9383
hERG inhibition (predictor II) Non-inhibitor 0.8673
Pharmacoeconomics
Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Everylife
  • Impax laboratories inc
  • Lannett co inc
  • Lederle laboratories div american cyanamid co
  • Eli lilly and co
  • Sandoz inc
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Silver Sulfadiazine 1% Cream 400 gm Jar36.48USDjar
Silver Sulfadiazine 1% Cream 50 gm Jar21.99USDjar
Silver Sulfadiazine 1% Cream 85 gm Jar19.99USDjar
Silver Sulfadiazine 1% Cream 25 gm Jar13.99USDjar
Sulfadiazine 500 mg tablet2.5USDtablet
Sulfazine EC 500 mg Enteric Coated Tabs0.42USDtab
Sulfazine ec 500 mg tablet0.38USDtablet
Sulfazine 500 mg tablet0.25USDtablet
Sulfadiazine powder0.13USDg
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point255.5 dec °CPhysProp
water solubility77 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-0.09HANSCH,C ET AL. (1995)
logS-3.51ADME Research, USCD
pKa6.36SANGSTER (1994)
Predicted Properties
PropertyValueSource
water solubility6.01e-01 g/lALOGPS
logP0.25ALOGPS
logP0.39ChemAxon
logS-2.6ALOGPS
pKa (strongest acidic)6.99ChemAxon
pKa (strongest basic)2.01ChemAxon
physiological charge-1ChemAxon
hydrogen acceptor count5ChemAxon
hydrogen donor count2ChemAxon
polar surface area97.97ChemAxon
rotatable bond count2ChemAxon
refractivity64.2ChemAxon
polarizability24.39ChemAxon
number of rings2ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterYesChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Charles L. Fox, Jr., Shanta M. Modak, Paul Fox, “Wound dressing comprising silver sulfadiazine incorporated in animal tissue and method of preparation.” U.S. Patent US4599226, issued September, 1977.

US4599226
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD00587
KEGG CompoundC07658
PubChem Compound5215
PubChem Substance46506164
ChemSpider5026
ChEBI9328
ChEMBLCHEMBL439
Therapeutic Targets DatabaseDAP001238
PharmGKBPA451539
Drugs.comhttp://www.drugs.com/cdi/sulfadiazine.html
WikipediaSulfadiazine
ATC CodesD06BA01J01EC02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSshow(73.5 KB)
Interactions
Drug Interactions
Drug
ChlorpropamideSulfonamide/sulfonylurea: possible hypoglycemia
CyclosporineThe sulfonamide decreases the effect of cyclosporine
FosphenytoinThe sulfonamide increases the effect of hydantoin
Methenamine mandelatePossible crystallization of urates with this combination
MethotrexateThe sulfamide increases the toxicity of methotrexate
PhenytoinThe sulfonamide increases the effect of hydantoin
TamoxifenSulfadiazine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfadiazine is initiated, discontinued or dose changed.
TolbutamideTolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.
TorasemideSulfadiazine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfadiazine is initiated, discontinued or dose changed.
TrimethoprimThe strong CYP2C9 inhibitor, Sulfadiazine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfadiazine is initiated, discontinued or dose changed.
WarfarinSulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfadiazine is initiated, discontinued or dose changed.
ZafirlukastSulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfadiazine is initiated, discontinued or dose changed.
Food InteractionsNot Available

Targets

1. Dihydropteroate synthetase

Kind: protein

Organism: Plasmodium falciparum

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Dihydropteroate synthetase Q27738 Details

References:

  1. de Araujo MV, Vieira EK, Silva Lazaro G, Conegero LS, Almeida LE, Barreto LS, da Costa NB Jr, Gimenez IF: Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94. Epub 2008 Mar 27. Pubmed
  2. Iliades P, Meshnick SR, Macreadie IG: Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs. Antimicrob Agents Chemother. 2005 Feb;49(2):741-8. Pubmed
  3. Prabhu V, Lui H, King J: Arabidopsis dihydropteroate synthase: general properties and inhibition by reaction product and sulfonamides. Phytochemistry. 1997 May;45(1):23-7. Pubmed

Enzymes

1. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 2E1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:10